Pune, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical CMO Market Size & Trends:
The Biopharmaceutical CMO Market size was evaluated at USD 15.3 billion in 2023. It is expected to reach USD 58.2 billion by 2032 at a high CAGR of 16.0% in the forecast period of 2024-2032.
The increased requirement for biopharmaceutical products and the outsourcing trend of manufacturing processes to specialized service providers are key growth drivers. CMOs are increasingly being utilized by biopharmaceutical companies to enhance their R&D efforts, optimize their operational efficiencies, and expedite the time-to-market for innovative therapies.
Market Overview
The market is experiencing rapid growth in the biopharmaceutical CMO market due to the significant demand for complex biopharmaceutical products. This corresponds to a robust supply of innovative therapeutic solutions with growing market demand for effective production. CMOs are being outsourced by many biopharmaceutical companies to focus on core competencies while internally reducing risks from the very high investment costs of in-house manufacturing facilities.
The dependency between a CMO and a biopharmaceutical company is critical in meeting the steadily expanding requirements for biologics, biosimilars, and other therapeutics. With the ever-changing landscape of global medicine in an evolutionary direction of more personalized treatments, the CMO comes in with the necessary expertise and capacity with technology support for the development and manufacturing of advanced therapies.
Get a Sample Report of Biopharmaceutical CMO Market@ https://www.snsinsider.com/sample-request/2938
Key Biopharmaceutical CMO Companies:
- Boehringer Ingelheim GmbH
- Lonza Group AG
- Inno Biologics Sdn Bhd
- Rentschler Biopharma SE
- JRS Pharma
- Biomeva GmbH
- ProBioGen AG
- Samsung Biologics
- Recipharm AB
- WuXi Biologics
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Toyobo Co., Ltd.
- Samsung Biologics
- Thermo Fisher Scientific Inc (Patheon & PPD)
- CMC Biologics
- WuXi Biologics
- AbbVie Inc.
- Binex Co., Ltd.
- Charles River Laboratories International, Inc.
- ICON Plc
- Parexel International Corporation
- Laboratory Corporation of America Holdings
- Siegfried Holding AG
- Cambrex Corporation
- Catalent, Inc., and others.
Biopharmaceutical CMO Market Report Scope:
| Report Attributes | Details |
| Market Size in 2023 | US$ 15.3 Billion |
| Market Size by 2032 | US$ 58.2 Billion |
| CAGR | CAGR of 16.0% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Biopharmaceutical CMO Market Segmentation Analysis
By Technology
The mammalian cell culture segment led the market with over 56.9% in 2023. The growth of this segment can be attributed to its ability to produce complex proteins with human-like post-translational modifications, which are of utmost importance in the development of therapeutic proteins. Steady growth toward complexity in the biologics market coupled with investments in the development of mammalian cell lines and process optimization further strengthened the growth of this segment.
By Services
The contract manufacturing services segment holds the biggest share in 2023 at more than 58.0%. This segment is witnessing an accelerated trend of R&D outsourcing activities. Rising biopharmaceutical companies are outsourcing such services to the CMOs for complete services from cell cultivation to fill-finish operations. As CMOs will enhance their service offerings to help biopharma companies overcome operational challenges, this trend shall not subside soon.
By Product
In 2023, the biologics segment dominated the market with more than 79.9% revenue share. This happened based on specificities and complexities in their manufacturing processes. The growth in this segment may be supported by further improvements in bioprocessing technologies and higher development budgets for biologics. The biosimilars segment will however grow at the highest CAGR of 8.7% as most companies are focusing on developing competitive alternatives to already established therapies thereby further increasing the demand for CMO support.
Biopharmaceutical CMO Market Key Segmentation:
By Source
- Mammalian
- Non-mammalian
By Service
- Contract Manufacturing
- Process Development
- Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
By Product
- Biologics
- Monoclonal antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
Do you have any specific queries or need any customization research on Biopharmaceutical CMO Market, Enquire Now@ https://www.snsinsider.com/enquiry/2938
Regional Insights
North America
In 2023, North America accounted for the largest share of 33.11% in the Biopharmaceutical CMO Market. These are the factors that have dominated this field. The reasons include well-established service providers, high numbers of approved products manufactured by the CMOs, and the growing interdependence among the companies with fewer in-house resources. The U.S. is also the hub for advanced biopharmaceutical research and manufacture, as more CMOs are extending their facilities to respond to the increasing demand from customers. Companies such as Lonza and Thermo Fisher Scientific hold a sizeable place in this regard, catering to the needs of customers by providing end-to-end solutions for the production of biologics.
Asia Pacific
Asia Pacific is expected to gain the biggest share in terms of growth through the biopharmaceutical CMO market, attributed to reforms in regulatory policies, infrastructural upgrades, and a considerable pool of potential clinical trial subjects. In this respect, investments are being seen in the region by US-headquartered biopharmaceutical companies, seeking cost-effective alternatives to production. There is now an emerging trend of outsourcing R&D and manufacturing activities in the region, especially in China. That country is also tipped to have maximum government support and a developed skilled workforce, and there will be increasing use of WuXi AppTec and Shenzhen Salubris Pharmaceuticals for such manufacturing.
Key Industry Developments
- March 2024: Lonza agreed with F. Hoffmann-La Roche Ltd to purchase the large-scale biologics manufacturing site owned by Roche in Vacaville, U.S.
- October 2023: Vaxcyte, Inc. broadened its agreement with Lonza to cover commercial manufacturing of its broad-spectrum pneumococcal conjugate vaccines (PCVs) around the world.
- August 2023: Samsung Biologics inaugurated the latest plant for biologics manufacturing in Incheon, South Korea; it forms part of its global expansion
Important Findings
- The Biopharmaceutical CMO Market is anticipated to grow with high outsourcing and the complexity of biologics.
- North America is still holding the lead, but Asia Pacific is showing rapid growth.
High investments in innovation and technology are causing growth in both the mammalian and the non-mammalian segments. - Recent deals indicate strategic expansions and partnerships that some major players in the biopharmaceutical CMO space are conducting.
Buy a Single-User PDF of Biopharmaceutical CMO Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/2938
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
- Incidence and Prevalence (2023)
- Prescription Trends, (2023), by Region
- Drug Volume: Production and usage volumes of pharmaceuticals.
- Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
7. Biopharmaceutical CMO Market Segmentation, by Source
8. Biopharmaceutical CMO Market Segmentation, by Service
9. Biopharmaceutical CMO Market Segmentation, by Product
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
Access Complete Report Details of Biopharmaceutical CMO Market Outlook 2024-2032@ https://www.snsinsider.com/reports/biopharmaceutical-cmo-market-2938
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
